Decoding and clinically applying the T-cell “dimmer switch”
BNX-IFSTM functional immune interaction profiling
OTS-412/HU for ICI-resistant patients
U.S. FDA and Korea MFDS cleared
Clinical validation–driven stepwise adaptive partnering
Bionoxx is advancing a dual translational strategy built on BNX-IFSTM (Immune Function Interaction System) and OTS-412/HU. BNX-IFSTM generates functional immune interaction data that are not detectable by conventional phenotyping or omics-based approaches, while OTS-412/HU translates this biology into a mechanism-based clinical program for ICI-resistant patients.
“Not more omics data, but a different kind of data.”
Activated T cells influence surrounding neutrophils through multiple mechanisms, leading to functional neutrophil diversification measurable by BNX-IFSTM.
This enables quantitative assessment of functional immune interaction states beyond conventional phenotyping and omics-based approaches.
OTS-412/HU is an immune-modulating oncolytic virus program designed to restore post-activation T-cell expansion using BNX-IFSTM-guided immune profiling.
Together, the platform and program create a direct path from functional immune interaction biology to clinical development and strategic partnering.
Bionoxx’s platform is built on clinical, translational, and reverse-translational evidence demonstrating that immune responses are governed by functional cell–cell interaction dynamics rather than static immune phenotypes.
Early clinical experience in oncolytic virotherapy, including Phase 1 and Phase 2a studies published in The Lancet Oncology and Nature Medicine, provided foundational human data linking viral therapy to adaptive immune modulation. These studies were further supported by mechanistic analyses reported in Science Translational Medicine, establishing a translational framework for immune response regulation.
Over the following decade, these clinical observations were systematically expanded and mechanistically refined through iterative translational and reverse-translational immunology research at Bionoxx, leading to the identification of functional immune regulation mediated by cell–cell interactions and ultimately establishing the conceptual and experimental foundation of the BNX-IFSTM platform.
This data-driven approach established a differentiated biological model in which immune responses are controlled by interaction-dependent functional states rather than static immune cell classification, supporting focused clinical application, biomarker development, and long-term strategic partnerships.
Bionoxx combines global patent protection with clinically embedded translational know-how that is difficult to replicate.
Bionoxx holds an extensive intellectual property estate surrounding OTS-412, including 40 granted patents and 81 patents across major jurisdictions (US, EP, JP, CN, AU, CA, KR), establishing strong global protection.
Complementing this foundation, Bionoxx is building a layered BNX-IFS™ intellectual property strategy to secure platform technology, biomarker applications, and mechanism-guided translational opportunities.
Beyond patents, BNX-IFS™ requires integrated expertise in clinical immunology, translational and reverse-translational immunology, and interaction-based immune profiling. Bionoxx is embedded within a university hospital environment and maintains long-standing collaborative networks with clinicians across nearby academic medical centers, enabling rapid validation of novel technologies in clinically relevant settings.
BNX-IFS™ provides a functional framework for interpreting disease-associated immune interaction states and linking them to clinical response.
Bionoxx’s proprietary BNX-IFS™ platform detects activated T cell–centered cell–cell interactions that are not captured by conventional CD phenotyping.
These interaction-dependent signals are quantitatively linked to disease progression and immune dysregulation in preclinical systems.
BNX-IFS™ interaction profiles clearly distinguish healthy individuals, cancer patients, and autoimmune disease patients.
These distinct signatures suggest that disease pathogenesis is associated with specific cell–cell interaction states.
Even across different diseases, patients with similar BNX-IFS™ interaction patterns respond to similar immune modulation strategies.
This supports a functional immune classification framework guiding mechanism-based clinical intervention.
OTS-412/HU is the clinical translation of Bionoxx’s interaction biology framework, designed to restore post-activation T-cell expansion in immune contexts where conventional immunotherapy response is limited.
The program applies BNX-IFSTM-guided immune profiling to identify functional immune states associated with response and resistance.
OTS-412/HU is being evaluated in ICI-resistant patients to modulate neutrophil–T cell interaction dynamics and restore systemic T-cell-dominant immunity.
The clinical program has received regulatory clearance from both the U.S. FDA and Korea MFDS, providing a path for mechanism-driven clinical translation.
Bionoxx is building a platform-driven ecosystem integrating capital, pharmaceutical partnerships, and large-scale functional immune data generation to accelerate mechanism-guided clinical development.
Bionoxx seeks venture capital and corporate venture capital partners to support the expansion of its BNX-IFS™ platform and the clinical development of OTS-412/HU.
Investment enables scaling of functional immune interaction datasets, integration into clinical trials, and rapid transition into adaptive expansion cohorts with strategic pharmaceutical partners.
Bionoxx partners with pharmaceutical companies to evaluate approved or pipeline compounds using BNX-IFS™ functional immune interaction profiling.
This enables mechanism-based patient selection, biomarker discovery, and rational combination strategies, forming the basis for co-developed, mechanism-guided clinical programs.
Bionoxx is establishing a BNX-IFS™ consortium to integrate multiple partners and generate large-scale functional immune datasets linked to clinical outcomes.
This consortium spans oncology, autoimmune, and inflammatory diseases, enabling cross-indication insights and creating shared infrastructure for mechanism-driven drug development and clinical translation.
